People: Acura Pharmaceuticals, Inc. (ACUR.O)
4.56USD
9 Feb 2010
$0.06 (+1.33%)
$4.56
--
$4.65
$4.50
14,355
17,501
$9.00
$4.00
Brzeczko, Albert
Brief Biography
Albert W. Brzeczko, Ph.D., has been Vice President, Technical Affairs of Acura Pharmaceuticals, Inc. since February 2009. From 1999 through 2009, Dr. Brzeczko was Vice President, Global Pharma New Product Development and Pharma Technologies for International Specialty Products, Inc., a contract services group specializing in the development of technologies for the bioenhancement of poorly soluble drugs. Prior to 1999, Dr. Brzeczko held various positions of increasing responsibility in pharmaceutical product development with UPM Pharmaceuticals, Banner Pharmacaps, Mylan Laboratories, and DuPont Merck. Dr. Brzeczko received a Bachelor of Science degree in biochemistry and a Ph.D. in pharmaceutical sciences from the University of Maryland.
Basic Compensation
| Total Annual Compensation, | Long-Term Incentive Plans, | All Other, | Fiscal Year Total, |
|---|---|---|---|
| -- | -- | -- | -- |
Options Compensation
| Quantity | Market Value | |
|---|---|---|
| Excercisable | -- | -- |
| Unexercisable | -- | -- |
| Excercised | -- | -- |
| Name | Fiscal Year Total |
|---|---|
| Markham, Richard | -- |
| Reddick, Andrew | 1,384,500 |
| Clemens, Peter | 583,500 |
| Jones, Robert | 1,059,420 |
| Seiser, Robert | 437,000 |
| Brzeczko, Albert | -- |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
